{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:07:38Z","timestamp":1791306458676,"version":"4.3.1"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1093\/ndt\/gfs388","type":"journal-article","created":{"date-parts":[[2012,10,8]],"date-time":"2012-10-08T21:57:29Z","timestamp":1349733449000},"page":"36-43","source":"Crossref","is-referenced-by-count":95,"title":["Aldosterone synthase inhibition in humans"],"prefix":"10.1093","volume":"28","author":[{"given":"Michel","family":"Azizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Amar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00ebl","family":"Menard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,10,8]]},"reference":[{"key":"key\n\t\t\t\t20170518090105_GFS388C1","first-page":"661","article-title":"Primary aldosteronism","volume":"45","author":"Conn","year":"1955","journal-title":"J Lab Clin Med"},{"key":"key\n\t\t\t\t20170518090105_GFS388C2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1210\/jc.2003-031337","article-title":"Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents","volume":"89","author":"Mulatero","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t20170518090105_GFS388C3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/er.2007-0030","article-title":"A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function","volume":"29","author":"Connell","year":"2008","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t20170518090105_GFS388C4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-53-2-259","article-title":"Electrolyte metabolism and aldosterone secretion in benign and malignant hypertension","volume":"53","author":"Laragh","year":"1960","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170518090105_GFS388C5","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/0002-9343(72)90050-2","article-title":"Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension","volume":"52","author":"Guyton","year":"1972","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20170518090105_GFS388C6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00004872-198404000-00008","article-title":"Body elemental composition, with particular reference to total and exchangeable sodium and potassium and total chlorine, in untreated and treated primary hyperaldosteronism","volume":"2","author":"Williams","year":"1984","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t20170518090105_GFS388C7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/01.mnh.0000165889.60254.98","article-title":"Aldosterone and end-organ damage","volume":"14","author":"Brown","year":"2005","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"key\n\t\t\t\t20170518090105_GFS388C8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2008.10.029","article-title":"Aldosterone and mineralocorticoid receptors: clinical studies and basic biology","volume":"301","author":"Funder","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"key\n\t\t\t\t20170518090105_GFS388C9","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renal damage in primary aldosteronism: results of the PAPY Study","volume":"48","author":"Rossi","year":"2006","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20170518090105_GFS388C10","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.HYP.0000258554.87444.91","article-title":"Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample","volume":"49","author":"Newton-Cheh","year":"2007","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20170518090105_GFS388C11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170518090105_GFS388C12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/jhh.2008.27","article-title":"High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle-aged caucasian populations","volume":"22","author":"Meneton","year":"2008","journal-title":"J Hum Hypertens"},{"key":"key\n\t\t\t\t20170518090105_GFS388C13","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"Hyperaldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20170518090105_GFS388C14","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","article-title":"Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion","volume":"168","author":"Gaddam","year":"2008","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170518090105_GFS388C15","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1210\/jc.2007-1088","article-title":"Body mass index predicts aldosterone production in normotensive adults on a high-salt diet","volume":"92","author":"Bentley-Lewis","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t20170518090105_GFS388C16","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1210\/jc.2009-2521","article-title":"Aldosterone production and insulin resistance in healthy adults","volume":"95","author":"Garg","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t20170518090105_GFS388C17","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.HYP.0000193502.77417.17","article-title":"Mechanisms of mineralocorticoid action","volume":"46","author":"Fuller","year":"2005","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20170518090105_GFS388C18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mce.2003.10.011","article-title":"The regulation of aldosterone synthase expression","volume":"217","author":"Bassett","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"key\n\t\t\t\t20170518090105_GFS388C19","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.HYP.0000201443.63240.a7","article-title":"Effects of aldosterone on the vasculature","volume":"47","author":"Schiffrin","year":"2006","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20170518090105_GFS388C20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11906-011-0182-2","article-title":"The role of aldosterone in the metabolic syndrome","volume":"13","author":"Briet","year":"2011","journal-title":"Curr Hypertens Rep"},{"key":"key\n\t\t\t\t20170518090105_GFS388C21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2012.03.002","article-title":"Human aldosterone synthase: recombinant expression in E. coli and purification enables a detailed biochemical analysis of the protein on the molecular level","author":"Hobler","year":"2012","journal-title":"J Steroid Biochem Mol Biol"},{"key":"key\n\t\t\t\t20170518090105_GFS388C22","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1515\/BC.2002.174","article-title":"The human steroid hydroxylases CYP1B1 and CYP11B2","volume":"383","author":"Bureik","year":"2002","journal-title":"Biol Chem"},{"key":"key\n\t\t\t\t20170518090105_GFS388C23","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.amjhyper.2007.05.008","article-title":"Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats","volume":"20","author":"Takeda","year":"2007","journal-title":"Am J Hypertens"},{"key":"key\n\t\t\t\t20170518090105_GFS388C24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.mce.2011.07.034","article-title":"Acute and chronic regulation of aldosterone production","volume":"350","author":"Hattangady","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"key\n\t\t\t\t20170518090105_GFS388C25","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1210\/jc.2005-0836","article-title":"Expression profiles for steroidogenic enzymes in adrenocortical disease","volume":"90","author":"Bassett","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t20170518090105_GFS388C26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2003.10.008","article-title":"The 45-year story of the development of an anti-aldosterone more specific than spironolactone","volume":"217","author":"Menard","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"key\n\t\t\t\t20170518090105_GFS388C27","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/HJH.0b013e32832810ed","article-title":"Aldosterone-receptor antagonism in hypertension","volume":"27","author":"Jansen","year":"2009","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t20170518090105_GFS388C28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170518090105_GFS388C29","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170518090105_GFS388C30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170518090105_GFS388C31","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/eurheartj\/ehn309","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)","volume":"29","author":"Dickstein","year":"2008","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170518090105_GFS388C32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20170518090105_GFS388C33","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170518090105_GFS388C34","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170518090105_GFS388C35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20170518090105_GFS388C36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00004872-200103000-00001","article-title":"A review of the medical treatment of primary aldosteronism","volume":"19","author":"Lim","year":"2001","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t20170518090105_GFS388C37","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t20170518090105_GFS388C38","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1161\/CIRCULATIONAHA.107.690396","article-title":"The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone\u2013renin ratio","volume":"116","author":"Hood","year":"2007","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170518090105_GFS388C39","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20170518090105_GFS388C40","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jash.2008.05.005","article-title":"Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension","volume":"2","author":"Calhoun","year":"2008","journal-title":"J Am Soc Hypertens"},{"key":"key\n\t\t\t\t20170518090105_GFS388C41","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","article-title":"Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial","volume":"57","author":"Vaclavik","year":"2011","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20170518090105_GFS388C42","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170518090105_GFS388C43","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170518090105_GFS388C44","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"key\n\t\t\t\t20170518090105_GFS388C45","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/01.hjh.0000226205.65442.f2","article-title":"Investigation of aldosterone-synthase inhibition in rats","volume":"24","author":"Menard","year":"2006","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t20170518090105_GFS388C46","first-page":"489","article-title":"The adrenal cortex","volume-title":"Williams Texbook of Endocrinology","author":"Orth","year":"1992"},{"key":"key\n\t\t\t\t20170518090105_GFS388C47","doi-asserted-by":"crossref","first-page":"A61.E583","DOI":"10.1016\/S0735-1097(10)60584-0","article-title":"Hormonal and electrolyte responses to the aldosterone synthase inhibitor lci699 in sodium depleted healthy subjects","volume":"55","author":"Menard","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170518090105_GFS388C48","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20170518090105_GFS388C49","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170518090105_GFS388C50","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1210\/jcem-69-4-896","article-title":"The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro","volume":"69","author":"Lamberts","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t20170518090105_GFS388C51","first-page":"1162","article-title":"The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis","volume":"70","author":"Demers","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t20170518090105_GFS388C52","first-page":"571","article-title":"The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects","volume":"74","author":"Trunet","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t20170518090105_GFS388C53","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/01.hjh.0000226183.98439.b3","article-title":"Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?","volume":"24","author":"Menard","year":"2006","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t20170518090105_GFS388C54","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ab.2009.07.025","article-title":"Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors","volume":"394","author":"LaSala","year":"2009","journal-title":"Anal Biochem"},{"key":"key\n\t\t\t\t20170518090105_GFS388C55","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","article-title":"Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage","volume":"111","author":"Fiebeler","year":"2005","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170518090105_GFS388C56","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/eurheartj\/ehn277","article-title":"Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone","volume":"29","author":"Mulder","year":"2008","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170518090105_GFS388C57","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/ki.2009.9","article-title":"Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt","volume":"75","author":"Lea","year":"2009","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20170518090105_GFS388C58","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1161\/HYPERTENSIONAHA.110.158543","article-title":"Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism","volume":"56","author":"Boulkroun","year":"2010","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20170518090105_GFS388C59","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bmcl.2010.11.040","article-title":"N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2)","volume":"21","author":"Zimmer","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"key\n\t\t\t\t20170518090105_GFS388C60","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/28\/1\/36\/13493912\/gfs388.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T10:16:38Z","timestamp":1562235398000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article-lookup\/doi\/10.1093\/ndt\/gfs388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,8]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,10,8]]},"published-print":{"date-parts":[[2013,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfs388","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10,8]]}}}